EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
- Petrovax Pharm is taking part in the international pharmaceutical exhibition CPhI Worldwide-2021
- Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's disease
- Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
- GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine
Research & Development
- High effectiveness of mix-and-match COVID-19 vaccines
- One coronavirus vaccine may protect against other coronaviruses
- Vaccines effective against most SARS-CoV-2 variants
- Scientists discover a highly potent antibody against SARS-CoV-2
- mRNA COVID vaccines highly effective at preventing symptomatic infection in health workers
- How to develop new drugs based on merged datasets
- New drug combination effective against SARS-CoV-2 infection
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
- FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
- FDA approves innovative treatment for pediatric patients with congenital athymia
- FDA authorizes software that can help identify prostate cancer
- FDA advances data, IT modernization efforts with new office of digital transformation